This 3-day educational program, offered by Congress by design and INC Research, teaches knowledge and skills needed by professionals in oncology drug development in the corporate and academic setting. 

It is the continuation of a highly successful program offered annually since 2004 and this year our Managing director Wouter Wijker will be presenting also. On Friday, 28 November Wouter Wijker will talk on adaptive designs in clinical trials (track: Biostatistics in oncology clinical trials).

Education offered

Oncology drug development is different from drug development in other therapeutic areas. The specific features of the preclinical and clinical development of new therapeutic agents for the treatment of cancer will be addressed during this course. The course will cover the complete development process, from preclinical development, through early-phase and late-phase clinical development, to post-registration clinical studies. It will also address essentials of tumor biology, medical oncology, hemato-oncology, tumor immunology and immunotherapy as well as biostatical and regulatory issues in the development of cancer therapeutics.

Download the programme

Why attending?

The course is intended for everyone wishing to acquire or improve his/her skills in the development of new cancer therapeutics. The education offered will be particularly useful for oncology drug development professionals in industry, the CRO environment, and academic research institutes, who recently entered the field of oncology.

For more information on the course, please check: